1993 Oct;25(4):329-41. doi: 10.2165/00003088-199325040-00006. Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. Clinical use of the azoles against fungal infections in renal transplant patients is complicated by the potentially major and unpredictable nature of drug‐drug interactions (DDIs) with the calcineurin inhibitors (CNIs). Find patient medical information for Zestril oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. 1, Nanchang, Jiangxi, 330006, China and Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, #639 Longmian Avenue, Nanjing, Jiangsu, 210009, China.Department of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaClinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaUse the link below to share a full-text version of this article with your friends and colleagues. Drug interactions of clinical significanceManagement of drug and food interactions with azole antifungal agents in transplant recipientsClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaEffect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitroCYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatmentEffect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomesInhibitory potential of antifungal drugs on ATP‐binding cassette transporters P‐glycoprotein, MRP1 to MRP5, BCRP, and BSEPPotential impact of cytochrome P450 3A5 in human liver on drug interactions with triazolesEffect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomesSolitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug‐drug interaction with rosuvastatin by causing up to a 2‐fold increase in statin exposureDisposition of azole antifungal agents. a Isolates of C. krusei are assumed to be intrinsically resistant to fluconazole and their MICs and/or zone diameters should not be interpreted using this scale. Like skateboarding and freeway ramps. Purpose: To assess the frequency of potential azole-drug interactions and consequences of interactions between fluconazole and other drugs in routine inpatient care. Bactrim inhibits CYP 2C9; which you remember is responsible for breaking down the more potent S-isomer of warfarin. Binding of fluconazole and other azoles in rat liverGreater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazoleInteraction between azole antifugals drugs and tacrolimus in four kidney transplant patientsEvaluation of the drug interaction between intravenous high‐dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patientsLow‐dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimusEffects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipientsFluconazole therapy in transplant recipients receiving FK506Prograf® (tacrolimus) U.S. Food and Drug Administration drug label, revised June 2019Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosingPharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantationPharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patientsTacrolimus trough level adjustment after administration of fluconazole to kidney recipientsEffect of fluconazole on blood levels of tacrolimusInterpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transplant Recipients, Select one or more newsletters to continue.